US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

9.62

-0.5700-5.59%

Volume:143.68K

Turnover:1.41M

Market Cap:534.64M

PE:-1.90

High:10.17

Open:10.16

Low:9.62

Close:10.19

52wk High:40.43

52wk Low:9.10

Shares:55.58M

Float Shares:19.23M

Volume Ratio:0.61

T/O Rate:0.75%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.53

PE(LYR):-0.52

Loading ...

Overview Company News Filings

Catalyst4 Reports $13.84 Million MapLight Therapeutics Common Share Purchase

MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies

Maplight Therapeutics Director Troy Cox Reports Purchase of 15,620 Shares Worth $148,702.4

MapLight Therapeutics price target lowered to $24 from $43 at Canaccord

MapLight downgraded to Equal Weight from Overweight at Morgan Stanley

MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.

U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit

Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34

THOMSON REUTERS

Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)

MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge

Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

MapLight Therapeutics announces topline results from ZEPHYR trial

MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia

Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2

THOMSON REUTERS

Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS

Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia

THOMSON REUTERS

Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events

THOMSON REUTERS

Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial

THOMSON REUTERS

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/MPLT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":9.62,"timestamp":1790878208423,"preClose":10.19,"halted":0,"volume":143680,"delay":0,"changeRate":-0.055937193326791,"floatShares":19234500,"shares":55575700,"eps":-5.058,"marketStatus":"Trading","change":-0.57,"latestTime":"10-01 14:10:09 EDT","open":10.16,"high":10.165,"low":9.62,"amount":1412875.1247999999,"amplitude":0.053484,"askPrice":9.65,"askSize":403,"bidPrice":9.58,"bidSize":36,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":10.19,"preHourTrading":{"tag":"盘前","latestPrice":10.15,"preClose":10.19,"latestTime":"09:29 EDT","volume":969,"amount":9874.010193,"timestamp":1790861399999,"change":-0.04,"changeRate":-0.003925,"amplitude":0.089303},"postHourTrading":{"tag":"盘后","latestPrice":10.19,"preClose":10.19,"latestTime":"19:30 EDT","volume":2199,"amount":22407.81,"timestamp":1790811003237,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.614236,"impliedVol":1.2282,"impliedVolPercentile":0.5402},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":19234500,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.614236,"shares":55575700,"dividePrice":0,"high":10.165,"amplitude":0.053484,"preClose":10.19,"low":9.62,"week52Low":9.1,"pbRate":"1.53","week52High":40.43,"institutionHeld":0,"latestPrice":9.62,"committee":-0.835991,"eps":-5.058,"divideRate":0,"volume":143680,"delay":0,"ttmEps":-5.058,"open":10.16,"prevYearClose":17.565,"prevWeekClose":10.46,"prevMonthClose":10.19,"prevQuarterClose":10.19,"fiveDayClose":10.76,"twentyDayClose":13.06,"sixtyDayClose":38.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-09-30","current":-1.926236,"percent":0.969697,"low":-9.047313,"twenty":-8.024668,"median":-7.290024,"eighty":-5.032174,"high":-2.251599,"avg":-6.529903,"sd":1.983813,"marketCap":564093547},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-09-04","current":-3.177455,"twenty":-8.055812,"median":-7.370362,"eighty":-6.26295,"marketCap":730264947},{"date":"2026-09-11","current":-3.333426,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"marketCap":766111286},{"date":"2026-09-18","current":-2.737351,"twenty":-8.049665,"median":-7.312639,"eighty":-6.03858,"marketCap":629117139},{"date":"2026-09-25","current":-2.601934,"twenty":-8.035579,"median":-7.308017,"eighty":-5.386392,"marketCap":597994736},{"date":"2026-09-30","current":-2.454427,"twenty":-8.024668,"median":-7.290024,"eighty":-5.032174,"marketCap":564093547}],"updateTime":1790865187159},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655384282","title":"Catalyst4 Reports $13.84 Million MapLight Therapeutics Common Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2655384282","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655384282?lang=en_us&edition=fundamental","pubTime":"2026-07-31 06:40","pubTimestamp":1785451206,"startTime":"0","endTime":"0","summary":"Catalyst4 reports $13.84 million MapLight Therapeutics common share purchaseCatalyst4, a 10% owner of Maplight Therapeutics, reported open-market purchases totaling 1,209,225 voting common shares.Purc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLfqNPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Catalyst4 Reports $13.84 Million MapLight Therapeutics Common Share Purchase","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655801359","title":"MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2655801359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655801359?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:26","pubTimestamp":1785425177,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $25.00. In addition to Jefferies, MapLight...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maplight-therapeutics-inc-mplt-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maplight-therapeutics-inc-mplt-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655342048","title":"Maplight Therapeutics Director Troy Cox Reports Purchase of 15,620 Shares Worth $148,702.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2655342048","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655342048?lang=en_us&edition=fundamental","pubTime":"2026-07-29 09:15","pubTimestamp":1785287721,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics director Troy Cox reports purchase of 15,620 shares worth $148,702.4Maplight Therapeutics director Troy Cox reported buying 15,620 shares of voting common stock at a weighted ave","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLb1bBRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maplight Therapeutics Director Troy Cox Reports Purchase of 15,620 Shares Worth $148,702.4","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654500961","title":"MapLight Therapeutics price target lowered to $24 from $43 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654500961?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:20","pubTimestamp":1785237629,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on MapLight Therapeutics (MPLT) to $24 from $43 and keeps a Buy rating on the shares. The firm updated it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006677","title":"MapLight downgraded to Equal Weight from Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006677?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:56","pubTimestamp":1785236218,"startTime":"0","endTime":"0","summary":"Morgan Stanley downgraded MapLight Therapeutics (MPLT) to Equal Weight from Overweight with a price target of $21, down from $34. While the ZEPHYR ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654058910","title":"MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2654058910","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654058910?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:28","pubTimestamp":1785234480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071164","title":"U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654071164?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:31","pubTimestamp":1785223918,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, IntuitJuly 28 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BioL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL4N43U0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRB","GOSS","BWFG","HUT","HTH","IP","CBOE","MSBI","BLFS","NEM","MPLT","INTU","FMBH","HIG","CHRW","CHMG","BKR","IDU","HAPN","LMT","PPA","DIPR","CUT","GTY","NEE","AGYS","STCE","LMTS","NVTS","BY","HBT","RNWZ","GDX","WDGF","FRPT","HCA","OTIS","BRBR","LW","CIFR","FFIV","OWL","SRCE","LMTL","PINE","CDNS","ENSG","CLSK","GSHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078237","title":"Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654078237?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:55","pubTimestamp":1785214549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654204494","title":"Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654204494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654204494?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:00","pubTimestamp":1785171618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Syensqo SA/NV (SHBBF) and MapLight Therapeutics, Inc. (MPLT)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654801068","title":"MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2654801068","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654801068?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:27","pubTimestamp":1785155262,"startTime":"0","endTime":"0","summary":"MapLight's schizophrenia drug fails once-daily test, shares plungeJuly 27 (Reuters)-MapLight TherapeuticsMPLT.Osaid on Monday its schizophrenia drug failed to show statistically significant symptom im","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU0882574055.USD","LU1585245621.USD","LU1571399168.USD","LU1868837300.USD","LU0306806265.USD","LU0306807586.USD","LU1323610961.USD","LU1093756168.USD","LU1291159041.SGD","LU0868494617.USD","LU0432979614.USD","LU2125154935.USD","BMY","LU1868836591.USD","LU0096364046.USD","LU0456855351.SGD","LU0267386448.USD","IE00B2B36J28.USD","BK4559","LU1032466523.USD","LU1670711040.USD","LU1868836914.USD","LU1670710588.SGD","LU1670711123.USD","IE0009355771.USD","LU1670710661.SGD","IE00BFXG1179.USD","BK4007","LU0321505868.SGD","BK4534","LU1074936037.SGD","LU2242646821.SGD","LU2133065610.SGD","IE00BJT1NW94.SGD","LU1430594728.SGD","BK4588","IHE","LU1983299246.USD","LU0225284248.USD","LU0061475181.USD","FTXH","LU2125154778.USD","LU1093756325.SGD","MPLT","LU1883839398.USD","LU1261432733.SGD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017731","title":"Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017731?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:12","pubTimestamp":1785154348,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012194","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012194","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012194?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:39","pubTimestamp":1785152371,"startTime":"0","endTime":"0","summary":"STAK  shares were down 55% in Monday premarket trading after the earlier session's 602% rally.MapLight Therapeutics  stock was down 55% after the company said a phase 2 trial of ML-007C-MA in schizophrenia met its primary endpoint, demonstrating a significant reduction in severity of the condition versus placebo.Profusa  shares were down 18% after the company signed a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company.Recon Technology  stock was down 15%, following the earlier session's 11.6% gain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PFSA","MPLT","STAK","BK4139","RCON","BK4179","BK4082"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2654014028","title":"MapLight Therapeutics announces topline results from ZEPHYR trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014028?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:16","pubTimestamp":1785150965,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) announced topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1814569148.SGD","LU1280957306.USD","LU0234570918.USD","LU0127658192.USD","FDFF","LU0912757837.SGD","LU2360107671.USD","LU2506951875.HKD","LU2552382058.USD","MA","BK4534","LU1691799644.USD","LU1989772923.USD","LU2764262908.HKD","SGXZ51526630.SGD","LU0198837287.USD","SG9999002232.USD","LU0061474705.USD","LU0353189680.USD","LU0642271901.SGD","LU2361044865.SGD","LU0006306889.USD","IE000SO60NU8.SGD","LU0170899867.USD","MPLT","LU0868494708.USD","LU0950375773.USD","LU2023250504.SGD","IPAY","SG9999000418.SGD","IE00BN29S564.USD","LU1868837300.USD","UYG","IYG","LU2237957811.SGD","LU1861217088.USD","LU1815333072.USD","BK4227","LU2403377893.USD","IE00BHPRN162.USD","FNCL","LU1974910355.USD","VFH","LU0345769631.USD","LU0109391861.USD","SG9999011175.SGD","STBQ","XLF","LU1629891620.HKD","LATR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014558","title":"MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014558?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150129,"startTime":"0","endTime":"0","summary":"MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophreniaMapLight Therapeutics reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in adults with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL3f19z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","MPLT","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","BCDF","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654143780","title":"Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2654143780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654143780?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654142010","title":"Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654142010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654142010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014822","title":"Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014822?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014373","title":"Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014373?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014340","title":"Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014340?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MA","BK4585","MPLT","BK4527","LU1316542783.SGD","LU1280957306.USD","FDFF","LU2168564149.EUR","LU1983260115.SGD","LU0708995401.HKD","LU0056508442.USD","LU1732800096.USD","BK4533","BK4139","UYG","LU1712237335.SGD","SG9999003800.SGD","IPAY","IE00BKDWB100.SGD","LU0642271901.SGD","LU0823417653.USD","LU2506951958.HKD","LU0823421416.USD","LU1815333072.USD","LU2092627202.USD","IYG","LU0107464264.USD","LU0096362180.USD","IE000WAW04H5.SGD","LU1718418525.SGD","BID","STBQ","LU0823434583.USD","LU0557290698.USD","LU1861217088.USD","VFH","FNCL","LU2360107671.USD","LATR","LU1868836914.USD","LU0061475181.USD","LU0210533765.USD","LU2420271590.USD","LU2077746001.SGD","IE00B4JS1V06.HKD","LU0823421333.USD","XLF","LU2168563687.JPY","LU2092937148.SGD","ASD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":120,"code":"91000000","status":"200"}]}}